Dr Shaun Chuah
- Clinical Senior Research Fellow (Immunology & Infection)
email:
Shaun.Chuah@glasgow.ac.uk
pronouns:
He/him/his
Research interests
My specific research interest lies in the application of machine learning to better understand the clinical behaviour and biology of inflammatory bowel disease. Gaining a deeper understanding will hopefully allow the development of better tools and treatment for patients in the clinic. To do this, I am currently developing scalable approaches to patient recruitment and data collection as well as novel end-to-end data pipelines to allow the development and deployment of machine learning models as useful clinical tools.
Current studies
- MUSIC Study (www.musicstudy.uk)
- MARVEL Study (www.marvelstudy.uk)
Background
I obtained my MBChB from the University of Edinburgh in 2013. After completing foundation and core training across both Edinburgh and Glasgow, I returned to Edinburgh to undertake specialty training in Gastroenterology. During this time, I earned a postgraduate Doctor of Medicine research degree, completing a thesis that characterised the behaviour of circulating cell-free DNA in inflammatory bowel disease in Dr. Gwo-Tzer Ho's lab.
During my time in research, I developed a specialist interest in software/data engineering/ machine-learning and understand the challenges of building robust, scalable, end-to-end data infrastructure to manage platform translational studies.
Publications
Prior publications
ORCiD
McAllister MJ, Hall R, Whelan RJ, Fischer LJ, Chuah CS, Cartlidge PD, Drury B, Rutherford DG, Duffin RM, Cartwright JA, Dorward DA, Rossi AG, Ho GT, (2024) Formylated Peptide Receptor-1-Mediated Gut Inflammation as a Therapeutic Target in Inflammatory Bowel Disease. Crohn's & colitis 360 (pmid: 38352118)(pmc: PMC10862654)(doi: 10.1093/crocol/otae003); source: Europe PubMed Central
Chuah CS, Fischer L, Ho GT, (2023) Circulating Cell-Free DNA in Inflammatory Bowel Disease: Liquid Biopsies with Mechanistic and Translational Implications. Faculty reviews (pmid: 37346090)(pmc: PMC10281509)(doi: 10.12703/r/12-14); source: Europe PubMed Central
Drury B, Chuah CS, Hall R, Hardisty GR, Rossi AG, Ho GT, (2023) Neutrophil-dependent Mitochondrial DNA Release Associated With Extracellular Trap Formation in Inflammatory Bowel Disease. Gastro hep advances (pmid: 39130118)(pmc: PMC11308081)(doi: 10.1016/j.gastha.2023.03.022); source: Europe PubMed Central
Philip DJ Dunne, Young D, Chuah CS, Hayes P, Tripathi D, Leithead J, Smith L, Gaya D, Forrest E, Stanley AJ, (2022) Letter: non-selective beta-blockers in cirrhosis-effect beyond portal hypertension. Authors' reply. Alimentary pharmacology & therapeutics (pmid: 35689317)(doi: 10.1111/apt.16982); source: Cher Shiong Chuah
Philip DJ Dunne, David Young, Chuah CS, Hayes PC, Tripathi D, Leithead J, Smith LA, Gaya DR, Ewan Forrest, Stanley AJ, (2022) Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial. Alimentary pharmacology & therapeutics (pmid: 35322892)(doi: 10.1111/apt.16901); source: Cher Shiong Chuah
Chuah S, Hall R, Ward E, Drury B, Ho G, (2022) Mitochondrial DAMPs as mechanistic biomarkers of mucosal inflammation in Crohn’s disease: Study protocol for prospective longitudinal cohort study in Scotland (ppr: PPR471572)(doi: 10.1101/2022.03.21.22270313); source: Europe PubMed Central
McAllister MJ, Kirkwood K, Chuah SC, Thompson EJ, Cartwright JA, Russell CD, Dorward DA, Christopher D Lucas, Gwo-tzer Ho, (2021) Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection. Inflammation (pmid: 34697723)(pmc: PMC8545358)(doi: 10.1007/s10753-021-01567-z); source: Cher Shiong Chuah
McAllister MJ, Kirkwood K, Chuah SC, Thompson EJ, Cartwright JA, Russell CD, Dorward DA, Lucas CD, Ho G, (2021) Intestinal Protein Characterisation of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in Inflammatory Bowel Disease (IBD) and Fatal COVID-19 Infection (ppr: PPR344461)(doi: 10.21203/rs.3.rs-495949/v1); source: Europe PubMed Central
Nikolas Plevris, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Wai Liam Lam, Saunders J, Kelly C, Gaya D, Jafferbhoy H, Jonathan Macdonald, Seenan JP, Craig Mowat, Naismith G, Potts LF, Sutherland DI, Watts D, Arnott I, Bain G, Jones G, Lees CW, (2021) Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. Journal of gastroenterology and hepatology (pmid: 33381875)(doi: 10.1111/jgh.15390); source: Cher Shiong Chuah
Hannah McDowell, Cher Shiong Chuah, Tripathi D, Stanley AJ, Ewan Forrest, Hayes PC, (2020) Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study. Alimentary pharmacology & therapeutics (pmid: 33296526)(doi: 10.1111/apt.16189); source: Cher Shiong Chuah
Nikolas Plevris, James Fulforth, Mathew Lyons, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Ian Arnott, Gareth-Rhys Jones, Lees CW, (2020) Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (pmid: 32798706)(doi: 10.1016/j.cgh.2020.08.022); source: Cher Shiong Chuah
Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Lees CW, (2019) Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. Journal of Crohn's & colitis (pmid: 30768123)(doi: 10.1093/ecco-jcc/jjz042); source: Europe PubMed Central
Plevris N, Jenkinson PW, Chuah CS, Lyons M, Merchant LM, Pattenden RJ, Arnott ID, Jones GR, Lees CW, (2019) Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. Frontline gastroenterology (pmid: 32133110)(pmc: PMC7043080)(doi: 10.1136/flgastro-2019-101197); source: Europe PubMed Central
Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW, (2019) Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. Inflammatory bowel diseases (pmid: 30335139)(doi: 10.1093/ibd/izy320); source: Europe PubMed Central
Plevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW, (2018) Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. Digestive diseases and sciences (pmid: 30535885)(doi: 10.1007/s10620-018-5406-8); source: Europe PubMed Central
Chuah CS, Noble C, Leitch A, (2018) Case of steroid-resistant Crohn's-associated bronchiolitis in the setting of quiescent gastrointestinal disease treated with infliximab. BMJ case reports (pmid: 30567117)(pmc: PMC6301768)(doi: 10.1136/bcr-2018-226934); source: Europe PubMed Central
Chuah C, Kirkbride R, Alston R, Irons J, (2013) Hydrogen ion concentration and coronary artery bypass graft surgery with and without cardiopulmonary bypass. Journal of cardiothoracic surgery (pmid: 23961957)(pmc: PMC3765549)(doi: 10.1186/1749-8090-8-184); source: Europe PubMed Central